Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression
- PMID: 26700241
- DOI: 10.1007/s00213-015-4187-4
Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression
Abstract
Rationale: In response to stress, corticotropin releasing hormone (CRH) and vasopressin (AVP) are released from the hypothalamus, activate their receptors (CRHR1, CRHR2 or AVPr1b), and synergistically act to induce adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Overstimulation of this system has been frequently associated with major depression states.
Objective: The objective of the study is to assess the role of AVP and CRH receptors in fluoxetine and venlafaxine effects on the expression of depression-related behavior.
Methods: In an animal model of depression (olfactory bulbectomy in mice, OB), we evaluated the effects of fluoxetine or venlafaxine (both 10 mg/kg/day) chronic administration on depression-related behavior in the tail suspension test. Plasma levels of AVP, CRH, and ACTH were determined as well as participation of their receptors in the expression of depression related-behavior and gene expression of AVP and CRH receptors (AVPr1b, CRHR1, and CRHR2) in the pituitary gland.
Results: The expression of depressive-like behavior in OB animals was reversed by treatment with both antidepressants. Surprisingly, OB-saline mice exhibited increased AVP and ACTH plasma levels, with no alterations in CRH levels when compared to sham mice. Chronic fluoxetine or venlafaxine reversed these effects. In addition, a significant increase only in AVPr1b gene expression was found in OB-saline.
Conclusion: The antidepressant therapy used seems to be more likely related to a reduced activation of AVP rather than CRH receptors, since a positive correlation between AVP levels and depressive-like behavior was observed in OB animals. Furthermore, a full restoration of depressive behavior was observed in OB-fluoxetine- or venlafaxine-treated mice only when AVP was centrally administered but not CRH.
Keywords: AVPr1b; CRHR1; Corticotropin releasing hormone; Depressive behavior; Fluoxetine; Vasopressin; Venlafaxine.
Similar articles
-
The role of the arginine vasopressin Avp1b receptor in the acute neuroendocrine action of antidepressants.Psychoneuroendocrinology. 2008 May;33(4):405-15. doi: 10.1016/j.psyneuen.2007.12.009. Epub 2008 Feb 4. Psychoneuroendocrinology. 2008. PMID: 18243568
-
Ghrelin effects expression of several genes associated with depression-like behavior.Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 2;56:227-34. doi: 10.1016/j.pnpbp.2014.09.012. Epub 2014 Oct 5. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25286107
-
Inferior petrosal sinus sampling in healthy subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion.J Clin Invest. 1996 May 1;97(9):2045-50. doi: 10.1172/JCI118640. J Clin Invest. 1996. PMID: 8621793 Free PMC article.
-
Vasopressin as a target for antidepressant development: an assessment of the available evidence.J Affect Disord. 2002 Nov;72(2):113-24. doi: 10.1016/s0165-0327(02)00026-5. J Affect Disord. 2002. PMID: 12200202 Review.
-
Corticotropin-releasing hormone and arginine vasopressin in depression focus on the human postmortem hypothalamus.Vitam Horm. 2010;82:339-65. doi: 10.1016/S0083-6729(10)82018-7. Vitam Horm. 2010. PMID: 20472147 Review.
Cited by
-
Ghrelin mediated regulation of neurosynaptic transmitters in depressive disorders.Curr Res Pharmacol Drug Discov. 2022 Jun 13;3:100113. doi: 10.1016/j.crphar.2022.100113. eCollection 2022. Curr Res Pharmacol Drug Discov. 2022. PMID: 35782191 Free PMC article. Review.
-
Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.Psychiatry Clin Neurosci. 2024 Sep;78(9):495-506. doi: 10.1111/pcn.13703. Epub 2024 Jun 25. Psychiatry Clin Neurosci. 2024. PMID: 38923665 Review.
-
The Interaction of Vasopressin with Hormones of the Hypothalamo-Pituitary-Adrenal Axis: The Significance for Therapeutic Strategies in Cardiovascular and Metabolic Diseases.Int J Mol Sci. 2024 Jul 5;25(13):7394. doi: 10.3390/ijms25137394. Int J Mol Sci. 2024. PMID: 39000501 Free PMC article. Review.
-
Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.Neuropsychiatr Dis Treat. 2023 Apr 12;19:811-828. doi: 10.2147/NDT.S402831. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37077711 Free PMC article. Review.
-
Vasopressin V1B Receptor Antagonists as Potential Antidepressants.Int J Neuropsychopharmacol. 2021 Jul 14;24(6):450-463. doi: 10.1093/ijnp/pyab013. Int J Neuropsychopharmacol. 2021. PMID: 33733667 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous